These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1548750)

  • 1. Functional comparison of the basic domains of the Tat proteins of human immunodeficiency virus types 1 and 2 in trans activation.
    Elangovan B; Subramanian T; Chinnadurai G
    J Virol; 1992 Apr; 66(4):2031-6. PubMed ID: 1548750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes.
    Bieniasz PD; Grdina TA; Bogerd HP; Cullen BR
    J Virol; 1999 Jul; 73(7):5777-86. PubMed ID: 10364329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus type 2 (HIV-2) trans-activator (Tat): functional domains and the search for trans-dominant negative mutants.
    Arya SK
    AIDS Res Hum Retroviruses; 1993 Sep; 9(9):839-48. PubMed ID: 8257633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous basic domain substitutions in the HIV-1 Tat protein reveal an arginine-rich motif required for transactivation.
    Subramanian T; Govindarajan R; Chinnadurai G
    EMBO J; 1991 Aug; 10(8):2311-8. PubMed ID: 2065667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.
    Modesti N; Garcia J; Debouck C; Peterlin M; Gaynor R
    New Biol; 1991 Aug; 3(8):759-68. PubMed ID: 1931822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis.
    Kuppuswamy M; Subramanian T; Srinivasan A; Chinnadurai G
    Nucleic Acids Res; 1989 May; 17(9):3551-61. PubMed ID: 2542902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second exon of Tat of HIV-2 is required for optimal trans-activation of HIV-1 and HIV-2 LTRs.
    Tong-Starksen SE; Baur A; Lu XB; Peck E; Peterlin BM
    Virology; 1993 Aug; 195(2):826-30. PubMed ID: 8337847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human chromosome-dependent and -independent pathways for HIV-2 trans-activation.
    Hart CE; Westhafer MA; Galphin JC; Ou CY; Bacheler LT; Petteway SR; Wasmuth JJ; Chen IS; Schochetman G
    AIDS Res Hum Retroviruses; 1991 Nov; 7(11):877-82. PubMed ID: 1760228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein.
    Kamine J; Subramanian T; Chinnadurai G
    Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8510-4. PubMed ID: 1924310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAR-independent activation of HIV-1 requires the activation domain but not the RNA-binding domain of Tat.
    Taylor JP; Kundu M; Khalili K
    Virology; 1993 Aug; 195(2):780-5. PubMed ID: 8337844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zn2+ binding to cysteine-rich domain of extracellular human immunodeficiency virus type 1 Tat protein is associated with Tat protein-induced apoptosis.
    Misumi S; Takamune N; Ohtsubo Y; Waniguchi K; Shoji S
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):297-304. PubMed ID: 15117453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The basic RNA-binding domain of HIV-2 Tat contributes to preferential trans-activation of a TAR2-containing LTR.
    Chang YN; Jeang KT
    Nucleic Acids Res; 1992 Oct; 20(20):5465-72. PubMed ID: 1437564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of the N-terminal domain of Tat protein of the human immunodeficiency virus type 1.
    Reddy MV; Desai M; Jeyapaul J; Prasad DD; Seshamma T; Palmeri D; Khan SA
    Oncogene; 1992 Sep; 7(9):1743-8. PubMed ID: 1501886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.
    Fong SE; Greenwood JD; Williamson JC; Derse D; Pallansch LA; Copeland T; Rasmussen L; Mentzer A; Nagashima K; Tobin G; Gonda MA
    Virology; 1997 Jul; 233(2):339-57. PubMed ID: 9217057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence.
    Tiley LS; Madore SJ; Malim MH; Cullen BR
    Genes Dev; 1992 Nov; 6(11):2077-87. PubMed ID: 1427073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The number of positively charged amino acids in the basic domain of Tat is critical for trans-activation and complex formation with TAR RNA.
    Delling U; Roy S; Sumner-Smith M; Barnett R; Reid L; Rosen CA; Sonenberg N
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6234-8. PubMed ID: 2068104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional substitution of the basic domain of the HIV-1 trans-activator, Tat, with the basic domain of the functionally heterologous Rev.
    Subramanian T; Kuppuswamy M; Venkatesh L; Srinivasan A; Chinnadurai G
    Virology; 1990 May; 176(1):178-83. PubMed ID: 2184574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the Tat basic domain on human immunodeficiency virus type 1 transactivation, using chemically synthesized Tat protein and Tat peptides.
    Vives E; Charneau P; van Rietschoten J; Rochat H; Bahraoui E
    J Virol; 1994 May; 68(5):3343-53. PubMed ID: 8151793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages.
    Murphy KM; Sweet MJ; Ross IL; Hume DA
    J Virol; 1993 Dec; 67(12):6956-64. PubMed ID: 8230418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular cloning and characterization of a cellular protein that interacts with the human immunodeficiency virus type 1 Tat transactivator and encodes a strong transcriptional activation domain.
    Yu L; Zhang Z; Loewenstein PM; Desai K; Tang Q; Mao D; Symington JS; Green M
    J Virol; 1995 May; 69(5):3007-16. PubMed ID: 7707527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.